MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To guage various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major trial targets were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though one of the exploratory ob... https://chrisi665xkv9.westexwiki.com/user